Biohit (BIOBV) H1 2025 earnings summary

Executive summary

• Revenue for January–June 2025 was EUR 7.4 million, up 0.3% year-over-year, with international sales comprising 98.6% of total revenue.

• Operating profit was EUR 1.2 million, representing 15.9% of revenue, despite Middle East disruptions; sales outside the region grew 14%.

• Investments in new production technology and expansion into new European markets were initiated, with highest regional growth in Asia.

• GastroPanel remains the key product, with ongoing projects in the UK, US, and EU for gastric cancer screening.

Financial highlights

• Operative EBITDA was EUR 1.4 million (18.3% of revenue), down from EUR 1.5 million year-over-year.

• Net profit for the period was EUR 0.9 million, a 24.9% decrease year-over-year.

• Earnings per share were EUR 0.06, down from EUR 0.08 in the prior year.

• Financial assets at period end totaled EUR 5.1 million, with an equity ratio of 74.1%.

• Cash flow from operating activities was negative EUR 1.3 million, mainly due to increased contract assets and strong June sales.

Outlook and guidance

• 2025 revenue is expected to rise to EUR 15.7–17.1 million, a 10–20% increase over 2024, with an operating profit margin of 10–20%.

• Strategic targets for 2025–2028 include 15–20% annual revenue growth and EBIT of at least 10% of revenue.